Allison A. Feduccia

Allison A. Feduccia

Auto-generated profile, based on publicly available information

Allison A. Feduccia

Psychedelic.Support, Project New Day, Santa Cruz, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Lancet Psychiatry
Verified
Journal Article
Closed access
MMMichael C Mithoefer
Michael C Mithoefer
AMAnn T Mithoefer
Ann T Mithoefer
AFAllison A Feduccia
Allison A Feduccia
LJLisa Jerome
Lisa Jerome
MWMark Wagner
Mark Wagner
RDRick Doblin
Rick Doblin

7 May 2019 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
MMMichael C. Mithoefer
Michael C. Mithoefer
AFAllison A. Feduccia
Allison A. Feduccia
LJLisa Jerome
Lisa Jerome
AMAnne Mithoefer
Anne Mithoefer
MWMark Wagner
Mark Wagner
RDRick Doblin
Rick Doblin
Background: Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Methods: Six randomized, double-blind, controlled clinical trials at five study sites were conducted from April 2004 to February 2017. Active doses of MDMA (75–125 mg, n = 72) or placebo/control doses (0–40 mg, n = 31) were administered to individuals with PTSD during manualized psychotherapy sessions in two or three 8-h sessions spaced a month apart. Three non-drug 90-min therapy sessions preceded the first MDMA exposure, and three to four followed each experimental session. Results: After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups − 22.0 (5.17), P < 0.001]. The between-group Cohen’s d effect size was 0.8, indicating a large treatment effect. After two experimental sessions, more participants in the active group (54.2%) did not meet CAPS-IV PTSD diagnostic criteria than the control group (22.6%). Depression symptom improvement on the BDI-II was greatest for the active group compared to the control group, although only trended towards significant group differences [MMRM, estimated mean difference (SE) between groups − 6.0 (3.03), P = 0.053]. All doses of MDMA were well tolerated, with some expected reactions occurring at greater frequency for the active MDMA group during experimental sessions and the 7 days following. Conclusions: MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD. These studies supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment. Trial registration: ClinicalTrials.gov Identifier: NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.

8 September 2018 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
ADAlicia L. Danforth
Alicia L. Danforth
CGCharles S. Grob
Charles S. Grob
CSChristopher Struble
Christopher Struble
AFAllison A. Feduccia
Allison A. Feduccia
NWNick Walker
Nick Walker
AEAmy Emerson
Amy Emerson
Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted.

1 June 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
AFAllison A. Feduccia
Allison A. Feduccia
MMMichael C. Mithoefer
Michael C. Mithoefer
MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA. MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants. The underlying psychological and neurological mechanisms for the robust effects in mitigating PTSD are being investigated in animal models and in studies of healthy volunteers. This review explores the potential role of memory reconsolidation and fear extinction during MDMA-assisted psychotherapy. MDMA enhances release of monoamines (serotonin, norepinephrine, dopamine), hormones (oxytocin, cortisol), and other downstream signaling molecules (BDNF) to dynamically modulate emotional memory circuits. By reducing activation in brain regions implicated in the expression of fear- and anxiety-related behaviors, namely the amygdala and insula, and increasing connectivity between the amygdala and hippocampus, MDMA may allow for reprocessing of traumatic memories and emotional engagement with therapeutic processes. Based on the pharmacology of MDMA and the available translational literature of memory reconsolidation, fear learning, and PTSD, this review suggests a neurobiological rationale to explain, at least in part, the large effect sizes demonstrated for MDMA in treating PTSD.

1 June 2020 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
KGKyle T. Greenway
Kyle T. Greenway
NGNicolas Garel
Nicolas Garel
LJLisa Jerome
Lisa Jerome
AFAllison A. Feduccia
Allison A. Feduccia
Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psyched...

20 November 2017 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
AFAllison A. Feduccia
Allison A. Feduccia
JHJulie Holland
Julie Holland
MMMichael C. Mithoefer
Michael C. Mithoefer